Sign in →

Test Code MSCG Collagenofibrotic Glomerulopathy Confirmation, Mass Spectrometry


Necessary Information


Preliminary pathology report, history, and electron microscopy images are required.



Specimen Required


Supplies: Pathology Packaging Kit (T554)

Specimen Type: Formalin-fixed, paraffin-embedded kidney tissue block

Collection Instructions: Do not send fixed tissue slides. Testing can only be done on paraffin-embedded tissue blocks.


Secondary ID

615298

Useful For

Aiding in the diagnosis of collagenofibrotic glomerulopathy

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
MLCPC Microdissection, Laser Capture No, (Bill Only) No
MSPTC Mass Spectrometry No, (Bill Only) No

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

CG Confirm, LC MS

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Frozen 
  Refrigerated 

Reject Due To

Fixed tissue slides
Wet/frozen tissue
Cytological smears
Nonformalin fixed tissue
Nonparaffin embedded tissue		 Reject

Clinical Information

Collagenofibrotic glomerulopathy (CG), also called collagen type III glomerulopathy, is a rare kidney disease characterized by large amounts of atypical type III collagen fibrils in the mesangium and subendothelial space of renal glomeruli. Liquid chromatography tandem mass spectrometry performed on microdissected glomeruli from patients with CG demonstrates a unique proteomic profile. The presence of type III collagen, in the appropriate clinical and pathological context, can be useful to establish a diagnosis of CG.

Interpretation

An interpretation will be provided.

Cautions

No significant cautionary statements

Clinical Reference

1. Chen X, Wan H, Xu W, Zhu J. Collagen type III glomerulopathy: Case report and review of the literature. Clin Nephrol. 2017;1:39-46

2. Dong J, Wei H, Han M, Guan Y, Wu Y, Li H. Collagen type III glomerulopathy: A case report and review of 20 cases. Exp Ther Med. 2015;10(4):1445-1449

3. Kurien AA, Larsen CP, Cossey N. Collagenofibrotic glomerulopathy. Clin Kidney J. 2015;8(5):543-547

4. Cohen AH. Collagen type III glomerulopathies. Adv Chronic Kidney Dis. 2012;19(2):101-106

5. Duggal R, Nada R, Rayat CS, Sakhuja V, Joshi K. Collagenofibrotic glomerulopathy - a review. Clin Kidney J. 2012;5(1):7-12

Method Description

Affected areas are removed from paraffin-embedded tissues by laser microdissection. Protein digestion is performed, followed by liquid chromatography tandem mass spectrometry.(Unpublished Mayo method)

Day(s) Performed

Monday through Friday

Report Available

7 to 15 days

Specimen Retention Time

Until reported

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82542

88380

LOINC Code Information

Test ID Test Order Name Order LOINC Value
MSCG CG Confirm, LC MS 65757-7

 

Result ID Test Result Name Result LOINC Value
615299 Interpretation 50595-8
615300 Participated in the Interpretation No LOINC Needed
615301 Report electronically signed by 19139-5
615302 Material Received 81178-6
615303 Disclaimer 62364-5
615304 Case Number 80398-1
617019 Gross Description 22634-0
617020 Addendum 35265-8

Reference Values

An interpretive report will be provided.